Y
ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Dermatology · Lancet · 2026-08-22

Phase 2b RCT in 393 biologic-naive adults with moderate-to-severe atopic dermatitis: all three rezpegaldesleukin doses reduced EASI more than placebo at week 16 (mean −53% to −61% vs −31%; p≤0.0002). Injection-site reactions occurred in 70% vs 4%.

RCTn = 393
Silverberg et al. Rezpegaldesleukin treatment of moderate-to-severe atopic dermatitis (REZOLVE-AD): final results from the 16-week induction period of an international, double-blind, placebo-controlled, randomised phase 2b study

Sign in to react

Enter your email and we send a one-time link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.